Published in AIDS Weekly, October 7th, 2002
With these results, the company confirmed plans to submit an NDA in the third quarter of this year.
FTC-301 is an ongoing 48-week, double-blind, placebo-controlled phase III trial comparing once-a-day Coviracil to Zerit (stavudine) given twice daily, each combined within a background regimen of Sustiva (efavirenz) and Videx EC (didanosine). A total of 571 patients were enrolled in the United States, Europe, Mexico, and South...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.